Trichek Adverse Reactions

The commonest adverse effects of fenofibrate therapy are gastrointestinal disturbances including anorexia, nausea, and gastric discomfort. Other adverse effects reported to occur less frequently include headache, dizziness, vertigo, fatigue, skin rashes, pruritis, photosensitivity, alopecia, impotence, anaemia, leucopenia, and thrombocytopenia. Raised serum-aminotransferase concentrations have occasionally been reported. Elevated creatine phosphokinase concentrations during fenofibrate therapy may be associated with a syndrome of myositis, myopathy, and rarely rhabdo- myolysis; patients with hypoalbuminaemia resulting from nephrotoxic syndrome or with renal impairment may be at increased risk. Fenofibrate should not be given with statins in patients with risk factors for myopathy. Bezafibrate may increase the lithogenic index, and there have been isolated reports of gallstones, although the risk from fibrates as a class is unclear.